- Conditions
- Elevated Intraocular Pressure
- Interventions
- Latanoprost ophthalmic solution, 0.005%, TC-002 latanoprost ophthalmic solution, 0.005%
- Drug
- Lead sponsor
- TearClear Corp
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 20
- States / cities
- Garden Grove, California • Glendale, California • Mission Hills, California + 16 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–58
of 58
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Primary Open-Angle Glaucoma (POAG), Ocular Hypertension (OHT)
- Interventions
- trabodenoson 6.0% / latanoprost 0.005% QD, trabodenoson 3.0% / latanoprost 0.005% QD, trabodenoson 6.0% / latanoprost 0.0025% QD, latanoprost 0.005% QD, latanoprost 0.0025% QD
- Drug
- Lead sponsor
- Inotek Pharmaceuticals Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 201 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Lexington, Massachusetts
- Conditions
- Glaucoma
- Interventions
- Travoprost, Latanoprost
- Drug
- Lead sponsor
- Massachusetts Eye and Ear Infirmary
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Open Angle Glaucoma, Ocular Hypertension
- Interventions
- NCX 470 0.1%, Latanoprost 0.005%
- Drug
- Lead sponsor
- Nicox Ophthalmics, Inc.
- Industry
- Eligibility
- 18 Years to 84 Years
- Enrollment
- 696 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 63
- States / cities
- Dothan, Alabama • Chandler, Arizona • Phoenix, Arizona + 54 more
- Conditions
- Glaucoma, Application Site Pigmentation Changes
- Interventions
- latanoprost, bimatoprost, travoprost
- Drug
- Lead sponsor
- Summa Health System
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 2
- States / cities
- Arlington Heights, Illinois • Akron, Ohio
- Conditions
- OAG - Open-Angle Glaucoma, OHT - Ocular Hypertension
- Interventions
- QLS-111-FDC, Latanoprost (0.005%)
- Combination Product · Drug
- Lead sponsor
- Qlaris Bio, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Largo, Florida
- Conditions
- Open-angle Glaucoma, Ocular Hypertension
- Interventions
- Vehicle of DE-126 Ophthalmic Solution, high dose of DE-126 Ophthalmic Solution, Topical ultra-low dose of DE-126 Ophthalmic Solution, Topical low dose of DE-126 Ophthalmic Solution, Topical medium dose of DE-126 Ophthalmic Solution, Topical high dose of DE-126 Ophthalmic Solution, 0.005% Latanoprost Ophthalmic Solution
- Drug
- Lead sponsor
- Santen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 241 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 12
- States / cities
- Artesia, California • Mission Hills, California • Newport Beach, California + 9 more
- Conditions
- Glaucoma
- Interventions
- Timolol, latanoprost
- Drug
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Industry
- Eligibility
- 36 Weeks to 18 Years
- Enrollment
- 139 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 7
- States / cities
- Pembroke Pines, Florida • Atlanta, Georgia • Indianapolis, Indiana + 3 more
- Conditions
- Glaucoma, Open-Angle, Ocular Hypertension
- Interventions
- PA5108 Ocular Implant low dose, PA5108 Ocular Implant, high dose, Latanoprost 0.005% Ophthalmic Solution
- Combination Product · Drug
- Lead sponsor
- PolyActiva Pty Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Newport Beach, California
- Conditions
- Open-angle Glaucoma, Ocular Hypertension
- Interventions
- DE-117 Low Dose ophthalmic solution, DE-117 Low/Middle Dose ophthalmic solution, DE-117 Middle Dose ophthalmic solution, DE-117 Middle/High Dose ophthalmic solution, DE-117 High Dose ophthalmic solution, latanoprost ophthalmic solution 0.005%
- Drug
- Lead sponsor
- Santen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 184 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 14
- States / cities
- Chandler, Arizona • Artesia, California • Glendale, California + 11 more